-
Mashup Score: 3Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages - 2 year(s) ago
CAR T cell therapies can fail when these cells disappear. Rehm and colleagues demonstrate a procedure for T memory stem cell-enrichment (TSCM) using FACS combined with bioreactor expansion. Despite low TSCM frequencies in patients, this technology is suitable for providing clinical scale BCMA CAR T cells, facilitating extended persistence and tumor control.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Quantification of cell-free DNAfor the analysis of CD19-CAR-T cells during lymphoma treatment - 2 year(s) ago
The study proves the feasibility to quantify cell-free CAR-DNA in lymphoma patients during CAR-T cell treatment by a novel digital-droplet PCR assay. Combined analysis of cell-free CAR-DNA and reference cell-free DNA displays CAR-T cell-mediated lymphoma killing in individual patients.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Quantification of cell-free DNAfor the analysis of CD19-CAR-T cells during lymphoma treatment https://t.co/vGfcrhVR9s #CART #bmtsm #CARTcell #immunotherapy #tcellrx #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT_Journal The pharma companies, so behind to provide these tools! https://t.co/IhPjU0rEUF
-
-
Mashup Score: 0Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells - 2 year(s) ago
We herein utilized AAV-CAR Tregs to create tolerogenic environments suppressing both capsid and AAV-delivered transgene responses allowing for continued transgene expression from transduced cells. This induced local immune tolerance may ultimately be safer clinically than systemic, broad-spectrum immune suppression.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
By analyzing 214 apheresis products and CAR-T cell manufacturing runs across multiple disease indications, IR and colleagues have established a threshold of 40% CD14 + cell content as the trigger for the introduction of a rapid plastic adherence monocyte depletion step to enable a 97% manufacturing success rate.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
The potential of CAR T cell immunotherapy can likely be extended when combined with genome editing. Cathomen and colleagues developed a GMP-compliant, automated process that integrates lentiviral CAR delivery with TRAC editing at clinical scale. Such protocols will facilitate the production of off-the-shelf products and their successful clinical application.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Engineering and Design of Chimeric Antigen Receptors - 4 year(s) ago
T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since the first clinical reports of their efficacy emerged 7 years ago, investigators have focused on the mechanisms and properties that make CARs effective or toxic, and their effects on T cell biology. Novel CAR designs…
Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing - 4 year(s) ago
Adeno-associated viral (AAV) vectors packaging the CRISPR-Cas9 system (AAV-CRISPR) can efficiently modify disease-relevant genes in somatic tissues with high efficiency. AAV vectors are a preferred delivery vehicle for tissue-directed gene therapy because of their ability to achieve sustained expression from largely non-integrating episomal genomes. However, for genome editizng applications,…
Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
Spinocerebellar ataxia type 3 (SCA3), or Machado-Joseph disease (MJD), is a progressive neurodegenerative disorder caused by a CAG expansion in the ATXN3 gene. The expanded CAG repeat is translated into a prolonged polyglutamine repeat in the ataxin-3 protein and accumulates within inclusions, acquiring toxic properties, which results in degeneration of the cerebellum and brain stem. In the…
Categories: Hem/Onc News and JournalsTweet
Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages https://t.co/8B3a3nYEy8 #CART #bmtsm #CARTcell #immunotherapy #tcellrx #CARTcells #CellTherapy #Genetherapy @ASTCT